These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 3349472

  • 1. Tumor markers carbohydrate antigens CA 19-9 and CA-50 and carcinoembryonic antigen in pancreatic cancer and benign diseases of the pancreatobiliary tract.
    Harmenberg U, Wahren B, Wiechel KL.
    Cancer Res; 1988 Apr 01; 48(7):1985-8. PubMed ID: 3349472
    [Abstract] [Full Text] [Related]

  • 2. Estimation of carbohydrate antigen (CA) 19-9 levels in pure pancreatic juice of patients with pancreatic cancer.
    Nishida K, Tasaki N, Miyagawa H, Yoshikawa T, Kondo M.
    Am J Gastroenterol; 1988 Feb 01; 83(2):126-9. PubMed ID: 3422536
    [Abstract] [Full Text] [Related]

  • 3. [Tumor markers of pancreatic cancer].
    Takami H, Hishinuma S, Shintoku J, Furuuchi T, Ogata Y, Abe O.
    Gan To Kagaku Ryoho; 1985 Feb 01; 12(2):212-9. PubMed ID: 3855615
    [Abstract] [Full Text] [Related]

  • 4. [Importance of the tumor-associated antigen CA 19-9 in the differential diagnosis of pancreatic diseases].
    Heptner G, Domschke S, Schneider MU, Domschke W.
    Dtsch Med Wochenschr; 1985 Apr 19; 110(16):624-8. PubMed ID: 3857159
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of serum pancreatic enzymes, carbohydrate antigen 19-9, and carcinoembryonic antigen in various pancreatic diseases.
    Satake K, Kanazawa G, Kho I, Chung Y, Umeyama K.
    Am J Gastroenterol; 1985 Aug 19; 80(8):630-6. PubMed ID: 2411125
    [Abstract] [Full Text] [Related]

  • 6. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
    Ozkan H, Kaya M, Cengiz A.
    Hepatogastroenterology; 2003 Aug 19; 50(53):1669-74. PubMed ID: 14571813
    [Abstract] [Full Text] [Related]

  • 7. [Tumor markers in the diagnosis of tumors in the subhepatic area].
    Dufek V, Petrtýl J, Klener P, Chmel J.
    Vnitr Lek; 1994 Jun 19; 40(6):350-3. PubMed ID: 8073643
    [Abstract] [Full Text] [Related]

  • 8. [Comparison between the gastrointestinal tumor antigen and the carcinoembryonic antigen in diseases of the digestive tract].
    Tappero G, Piantino P, Cerchier A, Pecchio F.
    Minerva Med; 1985 Apr 14; 76(16):765-70. PubMed ID: 2582313
    [Abstract] [Full Text] [Related]

  • 9. [Diagnostic usefulness and limitation of measuring pancreatic cancer associate antigen, SPan-1, in patients with pancreatic cancer].
    Satake K, Chung YS, Umeyama K, Takeuchi T, Kim YS.
    Gan To Kagaku Ryoho; 1989 Apr 14; 16(4 Pt 2-1):1139-46. PubMed ID: 2730018
    [Abstract] [Full Text] [Related]

  • 10. [Role of carcinoembryonic antigen, carbohydrate antigen 19-9 and cytology of bile in diagnosis of biliary and pancreatic cancer].
    Matsuda M, Shimizu Y, Chikamatsu E, Takayanagi K, Ishigure H, Murakami S, Odani K.
    Nihon Geka Gakkai Zasshi; 1991 Jun 14; 92(6):716-21. PubMed ID: 1886576
    [Abstract] [Full Text] [Related]

  • 11. [Carbohydrate antigen CA 19-9: value in pancreatic pathology].
    Venot J, Vincent D, Gainant A, Descottes B, Cessot F, Beck C.
    Gastroenterol Clin Biol; 1986 Mar 14; 10(3):208-10. PubMed ID: 3460925
    [Abstract] [Full Text] [Related]

  • 12. [Diagnostic usefulness of serum levels of pancreatic oncofetal antigen (POA) and CA 19-9 in pancreatic cancers: monitoring of postoperative recurrences].
    Takami H, Hishinuma S, Shintoku J, Ogata Y, Abe O.
    Gan No Rinsho; 1985 May 14; 31(6 Suppl):631-7. PubMed ID: 3861883
    [Abstract] [Full Text] [Related]

  • 13. Carbohydrate antigen 19-9 (CA 19-9) and carcinoembryonic antigen (CEA) in pancreatic cancer. Role of age and liver dysfunction.
    Del Favero G, Fabris C, Panucci A, Basso D, Plebani M, Baccaglini U, Leandro G, Burlina A, Naccarato R.
    Bull Cancer; 1986 May 14; 73(3):251-5. PubMed ID: 3530354
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Tumour markers in pancreatic cancer.
    Haglund C, Kuusela P, Roberts PJ.
    Ann Chir Gynaecol; 1989 May 14; 78(1):41-53. PubMed ID: 2667448
    [Abstract] [Full Text] [Related]

  • 16. [Clinical evaluation of CA 19-9, TPA, IAP and 5'-NPD-V as tumor markers of hepatocellular, bile duct and pancreas carcinoma].
    Takahashi H, Miyazaki H, Deura M, Shimizu Y, Asukata I, Kameda H.
    Gan No Rinsho; 1985 May 14; 31(6 Suppl):623-30. PubMed ID: 2411964
    [Abstract] [Full Text] [Related]

  • 17. CA 19-9 assay in differential diagnosis of pancreatic carcinoma from inflammatory pancreatic diseases.
    Piantino P, Andriulli A, Gindro T, Pecchio F, Masoero G, Cavallini G, Naccarato R, Dobrilla G.
    Am J Gastroenterol; 1986 Jun 14; 81(6):436-9. PubMed ID: 3458359
    [Abstract] [Full Text] [Related]

  • 18. Comparison of portal and peripheral blood levels of carcinoembryonic antigen, CA 19-9, and CA 125 tumor-associated antigens in patients with colorectal and pancreatic cancer.
    Talbot RW, Nagorney DM, Pemberton JH, Wieand HS, Ritts RE.
    Cancer Res; 1989 Feb 01; 49(3):542-3. PubMed ID: 2910474
    [Abstract] [Full Text] [Related]

  • 19. [Clinical evaluation of the tumor marker CA 19-9 in comparison with carcinoembryonic antigen (CEA) in surgical pre- and postoperative diagnosis].
    Lorenz M, Happ J, Hottenrott C, Maul FD, Baum RP, Hör G, Encke A.
    Nuklearmedizin; 1986 Feb 01; 25(1):9-14. PubMed ID: 3459133
    [Abstract] [Full Text] [Related]

  • 20. [The role of CEA, CA 19-9 and TPA in the diagnosis of pancreatic cancer. Evaluation by discriminant analysis].
    Basso D, Fabris C, Del Favero G, Panucci A, Piccoli A, Plebani M, Pedrazzoli S, Baccaglini U, Lise M, Burlina A.
    Minerva Med; 1986 Apr 14; 77(16):613-6. PubMed ID: 3458035
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.